<div class="feed-description">Modern medicine increasingly relies on targeted drug delivery, a process during which therapeutic molecules are transported directly to specific organs or even certain cell types. To do this, drugs are often packaged inside biocompatible particles (nanoparticles), commonly composed of different fat molecules. <p> The efficiency of the delivery process is determined by many characteristics of the particles.</div>
<div class="feed-description">In the United States, prostate cancer is a leading cause of cancer-related disease and death in men. <p> About half of prostate cancer cases in patients of European ancestry have a gene rearrangement where the genes TMPRSS2 and ERG are fused together. This causes the ERG protein to be turned on, increasing the growth and migration of tumor cells.</div>
<div class="feed-description">Accumulation of DNA damage in the brain’s neurons may contribute to the development of Alzheimer’s disease. New research in FEBS Open Bio demonstrates the therapeutic potential of a drug that targets this process. <p> Using a mouse model of Alzheimer’s disease, investigators found that treatment with KCL-286, a molecule that activates the retinoic acid receptor-β (RARβ), enhanced the repair of DNA damage in neurons.</div>
<div class="feed-description">Researchers at The University of Texas MD Anderson Cancer Center were able to eradicate measurable residual disease (MRD) in B-cell acute lymphoblastic leukemia (ALL) patients, a critical step in improving long-term survival outcomes, by treating with the antibody-drug conjugate (ADC) inotuzumab ozogamicin. <p> Results from the Phase 2 study were published in Blood Cancer Journal. Among 37 patients treated, 70% achieved MRD negativity, including strong responses in both Philadelphia chromosome-positive and -negative disease.</div>
<div class="feed-description">A Monash University-led study has found that an unusual pairing of two commonly used antibiotics can kill and stop the spread of resistance in a highly drug-resistant bacterium, Pseudomonas aeruginosa, which can cause life-threatening bloodstream infections, pneumonia and meningitis. <p> Published in The Lancet Microbe, Monash Institute of Pharmaceutical Sciences (MIPS) researchers used a validated laboratory infection system in which they were able to expose bacterial samples from infected patients to simulated antibiotic dosing regimens, as would actually occur in hospitalised patients.</div>
<div class="feed-description">Cholesterol-related heart disease remains the leading cause of death worldwide, and while doctors have more tools than ever to treat it, many patients still can't achieve safe cholesterol levels, or can't tolerate the side effects of available medications. Now, researchers from University of California San Diego School of Medicine have uncovered a hidden biological pathway that explains why high-cholesterol diets steadily chip away at our body's ability to clear harmful low-density lipoprotein (LDL) cholesterol from the blood,</div>
<div class="feed-description">Developing new medicines can require thousands of chemistry experiments to identify the right recipe for a safe, effective and ideally affordable drug. <p> The process is slow and labor-intensive, and many of the reactions depend on hard-to-source metals that act as essential catalysts.</div>
<div class="feed-description">Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have developed a new platform that combines 3D bioprinting, advanced imaging and artificial intelligence to better monitor how cancer responds to treatment. The technology could help researchers identify promising cancer therapies more rapidly and provide a way to test treatments on a patient's own tumor cells, helping guide more personalized treatment decisions.</div>
<div class="feed-description">For the 18 million people living with rheumatoid arthritis, disease management currently means a lifetime of injections - a reality that new research from Tsinghua University may soon begin to change. Current first-line biologics targeting tumor necrosis factor (TNF) - including adalimumab (Humira), long among the world’s best-selling drugs - require injections every two weeks, potentially for decades. Prolonged use drives anti-drug antibody (ADA) formation in many patients, eroding therapeutic benefit and causing secondary treatment failure.</div>
<div class="feed-description">New antibiotic candidates for drug-resistant bacteria may reside inside prions, mis-folded protein in the brain best known for rare and fatal degenerative brain diseases. Prion and prion-like proteins may hide short peptides, named “prionins,” that can kill bacteria, suggesting proteins best known for their role in neurodegeneration may contain molecular features linked to immune defense, according to new research from the Perelman School of Medicine at the University of Pennsylvania.</div>
Chen's Blog，分享安全领域的所思、所想、所学。
空鸣深语
无论你是游戏死忠，还是轻度的休闲玩家，在这里都能找到感兴趣的东西。
要闻快讯
分享免费、小巧、实用、有趣、绿色的软件